HC Wainwright & Co. Maintains Buy on Perspective Therapeutics, Raises Price Target to $12
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Robert Burns maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target from $10 to $12.
HC Wainwright & Co. analyst Robert Burns maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target from $10 to $12.